Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis
Authors:
Open Access
- 1 July 2017
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 91, 1065-1074
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Development Program of Guangxi Province of China (guikeneng12237007)
- Guangxi Provincial Natural Science Foundation of China (2015GXNSFAA139194)
This publication has 32 references indexed in Scilit:
- Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from naturePharmacological Research, 2016
- The relevance of cell type- and tumor zone-specific VEGFR-2 activation in locally advanced colon cancerJournal of Experimental & Clinical Cancer Research, 2015
- Rationally Designed Multitarget Anticancer AgentsCurrent Medicinal Chemistry, 2013
- Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseasesThe Journal of Biochemistry, 2012
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and AntiangiogenesisClinical Cancer Research, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Vascular Endothelial Growth Factor Receptor-2 Couples Cyclo-Oxygenase-2 with Pro-Angiogenic Actions of Leptin on Human Endothelial CellsPLOS ONE, 2011
- Network medicine: a network-based approach to human diseaseNature Reviews Genetics, 2010
- Angiogenesis in life, disease and medicineNature, 2005
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971